In this issue:
Effect of volume CT screening on lung cancer mortality
First-line osimertinib in EGFR-mutated advanced NSCLC
Osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Osimertinib in NSCLC patients with uncommon EGFR mutations
Entrectinib in ROS1 fusion-positive NSCLC
Ganetespib + docetaxel in advanced NSCLC
Realworld use of checkpoint inhibitors in older adults with NSCLC
Impact of pembrolizumab + chemotherapy on QoL in squamous NSCLC
PD-L1 expression and outcomes in TKI-treated EGFR-mutated adenocarcinoma
Dietary fibre, yoghurt consumption and lung cancer risk
Please login below to download this issue (PDF)